LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

Home・Akciju saraksts・Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals Inc

Slēgts

SektorsVeselības aprūpe

81.85 0.94

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

80.76

Max

82.98

Galvenie mērījumi
By Trading Economics
Ienākumi	-252M -129M
Pārdošana	-295M 157M
Peļņas marža	-82.062
Darbinieki	1,069
EBITDA	-254M -103M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+20.62% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 25. febr.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	1.4B 13B
Iepriekšējā atvēršanas cena	80.91
Iepriekšējā slēgšanas cena	81.85

Ziņu noskaņojums

By Acuity

58%

42%

302 / 351 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Neutral Evidence

29.78 / 33.645 Atbalsts un pretestība

Ionis Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 18. febr. 22:31 UTC

Peļņas

Brambles Raises Dividend, Cash-Flow Guidance as 1st Half Profit Jumps -- Update

2026. g. 18. febr. 22:18 UTC

Peļņas

Wal-Mart de Mexico 4Q Profit Falls, Hit by Higher Taxes

2026. g. 18. febr. 22:11 UTC

Peļņas

Wesfarmers Boosts Dividend After 1st Half Profit Rises -- Update

2026. g. 18. febr. 21:52 UTC

Peļņas

Telstra Boosts Dividend as First-Half Earnings Rise 5.5% -- Update

2026. g. 18. febr. 23:56 UTC

Tirgus saruna

Santos's Review of Domestic Assets Could Lead to Simpler Portfolio -- Market Talk

2026. g. 18. febr. 23:46 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 18. febr. 23:46 UTC

Tirgus saruna

Nikkei May Rise After U.S. Tech Stock Gains -- Market Talk

2026. g. 18. febr. 23:34 UTC

Tirgus saruna

Peļņas

Brambles' Cost Control Stands Out to Bull -- Market Talk

2026. g. 18. febr. 23:33 UTC

Tirgus saruna

Gold Edges Higher Amid Growing Risks of U.S.-Iran Conflict -- Market Talk

2026. g. 18. febr. 23:32 UTC

Tirgus saruna

Australia Jobs Data Will Likely Support May Hike Assumptions -- Market Talk

2026. g. 18. febr. 22:45 UTC

Peļņas

DoorDash Stock Rebounds. Earnings and Revenue Both Fall Short. -- Barrons.com

2026. g. 18. febr. 22:44 UTC

Tirgus saruna

Investors Eyeing Nvidia's Revenue Visibility Ahead of 4Q Print -- Market Talk

2026. g. 18. febr. 22:37 UTC

Peļņas

Nutrien 4Q EPS $1.18 >NTR.T

2026. g. 18. febr. 22:37 UTC

Peļņas

Nutrien 4Q Sales $5.34B >NTR.T

2026. g. 18. febr. 22:35 UTC

Peļņas

Pan American Silver 4Q EPS $1.07 >PAAS

2026. g. 18. febr. 22:35 UTC

Peļņas

Pan American Silver 4Q Rev $1.18B >PAAS

2026. g. 18. febr. 22:30 UTC

Peļņas

Kinross Gold Raises Quarterly Dividend to 4c Vs. 3.5c >K.T

2026. g. 18. febr. 22:29 UTC

Peļņas

Kinross Gold 4Q EPS 75c >K.T

2026. g. 18. febr. 22:22 UTC

Peļņas

Coeur Mining: Full-Yr 2026 Production Is Expected to Be 55,000 - 65,000 Ounces of Gold and 5.5M - 6.3M Ounces of Silver >CDE

2026. g. 18. febr. 22:22 UTC

Tirgus saruna

Nvidia 4Q Earnings Coming Amid China Export Battle -- Market Talk

2026. g. 18. febr. 22:16 UTC

Peļņas

Brambles Raises Dividend, Cash-Flow Guidance as 1H Profit Jumps -- Update

2026. g. 18. febr. 22:05 UTC

Peļņas

Pan American Silver Reports Record Fourth Quarter And Full Year 2025 Financial Results; Record Cash Flow From Operations Of $554 Million In The Fourth Quarter; Dividend Increased By 29% >PAAS

2026. g. 18. febr. 22:03 UTC

Peļņas

Kaiser Aluminum Expects to Improve Conversion Rev by 5% to 10% and Adj EBITDA by 5% to 15% for FY26 >KALU

2026. g. 18. febr. 22:02 UTC

Peļņas

Kaiser Aluminum 4Q Adj EPS $1.53 >KALU

2026. g. 18. febr. 22:02 UTC

Peļņas

Kaiser Aluminum 4Q Sales $929M >KALU

2026. g. 18. febr. 22:02 UTC

Peļņas

Kaiser Aluminum 4Q EPS $1.68 >KALU

2026. g. 18. febr. 22:00 UTC

Peļņas

Kinross Gold 4Q Adj EPS 67c >KGC

2026. g. 18. febr. 22:00 UTC

Peļņas

Kinross Gold 4Q Sales $2.02B >KGC

2026. g. 18. febr. 21:56 UTC

Peļņas

Wesfarmers Boosts Dividend After 1H Profit Rises -- Update

2026. g. 18. febr. 21:50 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

Salīdzinājums

Cenas izmaiņa

Ionis Pharmaceuticals Inc Prognoze

Cenas mērķis

By TipRanks

20.62% augšup

Prognoze 12 mēnešiem

Vidējais 97.22 USD 20.62%

Augstākais 110 USD

Zemākais 87 USD

Pamatojoties uz 10 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Ionis Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

10 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 10 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Ionis Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

29.78 / 33.645Atbalsts un pretestība

The bullish and bearish events are balanced.

All events are bullish.

All events are bearish.

Noskaņojums

By Acuity

302 / 351 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.